Related Articles for PubMed (Select 18226196)

Severe skin reaction secondary to concomitant radiotherapy plus cetuximab.

Berger B, Belka C.

Radiat Oncol. 2008 Jan 28;3:5.

PMID: 18226196 [PubMed - in process]

Related Articles Free article in PMC

Cetuximab: an epidermal growth factor receptor chemeric human-murine monoclonal antibody.

Harding J, Burtness B.

Drugs Today (Barc). 2005 Feb;41(2):107-27. Review.

PMID: 15821783 [PubMed - indexed for MEDLINE]

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck.

Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK.

N Engl J Med. 2006 Feb 9;354(6):567-78.

PMID: 16467544 [PubMed - indexed for MEDLINE]

Cetuximab: a review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal cancer.

Blick SK, Scott LJ.

Drugs. 2007;67(17):2585-607. Review.

PMID: 18034592 [PubMed - indexed for MEDLINE]

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.

Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA; Eastern Cooperative Oncology Group.

J Clin Oncol. 2005 Dec 1;23(34):8646-54. Erratum in: J Clin Oncol. 2006 Feb 1;24(4):724.

PMID: 16314626 [PubMed - indexed for MEDLINE]

Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.

Huang S, Armstrong EA, Benavente S, Chinnaiyan P, Harari PM.

Cancer Res. 2004 Aug 1;64(15):5355-62.

PMID: 15289342 [PubMed - indexed for MEDLINE]

Cetuximab combined with radiotherapy: an alternative to chemoradiotherapy for patients with locally advanced squamous cell carcinomas of the head and neck?

Bernier J, Schneider D.

Eur J Cancer. 2007 Jan;43(1):35-45. Epub 2006 Nov 13. Review.

PMID: 17098420 [PubMed - indexed for MEDLINE]

Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.

Wong SF.

Clin Ther. 2005 Jun;27(6):684-94. Review.

PMID: 16117976 [PubMed - indexed for MEDLINE]

Anti-EGFR therapies: clinical experience in colorectal, lung, and head and neck cancers.

Vokes EE, Chu E.

Oncology (Williston Park). 2006 Apr;20(5 Suppl 2):15-25. Review.

PMID: 16736979 [PubMed - indexed for MEDLINE]

10:

Cetuximab in the treatment of head and neck cancer.

Bernier J.

Expert Rev Anticancer Ther. 2006 Nov;6(11):1539-52. Review.

PMID: 17134359 [PubMed - indexed for MEDLINE]

11:

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.

Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J, Baselga J, Rowinsky EK, Amellal N, Comte S, Bonner JA.

J Clin Oncol. 2007 Jun 1;25(16):2191-7. Erratum in: J Clin Oncol. 2007 Aug 20;25(24):3790.

PMID: 17538164 [PubMed - indexed for MEDLINE]

12:

The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.

Raben D, Helfrich B, Chan DC, Ciardiello F, Zhao L, Franklin W, Barón AE, Zeng C, Johnson TK, Bunn PA Jr.

Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):795-805.

PMID: 15701870 [PubMed - indexed for MEDLINE]

13:

Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, Kulmala J, Pulkkinen J, Grenman R, Elenius K.

Clin Cancer Res. 2006 Jul 1;12(13):4103-11.

PMID: 16818711 [PubMed - indexed for MEDLINE]

14:

Cetuximab in squamous cell head and neck carcinomas.

Gebbia V, Giuliani F, Valori VM, Agueli R, Colucci G, Maiello E.

Ann Oncol. 2007 Jun;18 Suppl 6:vi5-7. Review.

PMID: 17591832 [PubMed - indexed for MEDLINE]

15:

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.

Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW.

J Clin Oncol. 2001 Jul 1;19(13):3234-43.

PMID: 11432891 [PubMed - indexed for MEDLINE]

16:

Monoclonal antibodies targeting epidermal growth factor receptor and vascular endothelial growth factor with a focus on head and neck tumors.

Caponigro F, Formato R, Caraglia M, Normanno N, Iaffaioli RV.

Curr Opin Oncol. 2005 May;17(3):212-7. Review.

PMID: 15818163 [PubMed - indexed for MEDLINE]

17:

Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.

Pfister DG, Su YB, Kraus DH, Wolden SL, Lis E, Aliff TB, Zahalsky AJ, Lake S, Needle MN, Shaha AR, Shah JP, Zelefsky MJ.

J Clin Oncol. 2006 Mar 1;24(7):1072-8.

PMID: 16505426 [PubMed - indexed for MEDLINE]

18:

Epidermal growth factor receptor--its expression and copy numbers of EGFR gene in patients with head and neck squamous cell carcinomas.

Mrhalova M, Plzak J, Betka J, Kodet R.

Neoplasma. 2005;52(4):338-43.

PMID: 16059652 [PubMed - indexed for MEDLINE]

19:

Effect of epidermal growth factor receptor inhibitor class in the treatment of head and neck cancer with concurrent radiochemotherapy in vivo.

Feng FY, Lopez CA, Normolle DP, Varambally S, Li X, Chun PY, Davis MA, Lawrence TS, Nyati MK.

Clin Cancer Res. 2007 Apr 15;13(8):2512-8.

PMID: 17438112 [PubMed - indexed for MEDLINE]

20:

Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck.

Herbst RS, Arquette M, Shin DM, Dicke K, Vokes EE, Azarnia N, Hong WK, Kies MS.

J Clin Oncol. 2005 Aug 20;23(24):5578-87. Epub 2005 Jul 11.

PMID: 16009949 [PubMed - indexed for MEDLINE]

Recent Activity